5501 Fortunes Ridge Drive, Suite O, Durham, North Caroline, 27713 United StatesStem Genomics is a biotechnology company based in France and the United States, specialized in the design and delivery of innovative testing technologies for stem cells. A spin-out of the Institute for Regenerative Medicine & Biotherapy (IRMB), Stem Genomics was co-founded by Prof. John De Vos and Dr. Said Assou, internationally recognized experts in stem cell genomic integrity. The company emerged from a prestigious scientific environment at the heart of the University Hospital Centre of Montpellier, where the IRMB brings together research teams dedicated to fundamental stem cell research and the development of innovative applications for regenerative medicine, with the goal of accelerating the transfer from research to clinical applications. Founded in 2018, Stem Genomics now works with more than 150 clients worldwide, including academic institutions, biotechnology companies, and core facilities. North American clients are supported through our laboratory located in the Research Triangle in Durham, North Carolina, while European and other international clients are served from our headquarters in Montpellier, France. Stem Genomics is driven by a team of passionate and committed scientists whose mission is to support researchers in generating high-quality, reliable cell lines. We have developed strong in-house expertise in stem cell biology and advanced genetic stability assay technologies, enabling us to perform most analyses on our own platforms. In parallel, our R&D team continuously develops next-generation quality control assays. We pride ourselves on our responsiveness, availability, and close collaboration with our clients throughout the entire testing process. Testing Services Available in Europe and the United States: - Genomic Stability 1) iCS-digital PSC assay: Detects up to 93% of the most frequent abnormalities observed in human pluripotent stem cells within 3 days. The assay relies on a set of 28 specific probes targeting the most frequently affected genomic regions, including the 20q amplification, which represents approximately 23% of recurrent abnormalities in hPSCs and is often too small to be detected by G-banding karyotyping. 2) G-banding karyotype: Detects structural and numerical variants larger than 5–10 Mb. Turnaround time is approximately 20 business days in Europe and 10 business days in the United States. The assay can be performed on live or frozen cells and is applicable to any cell type. 3) Duo iCS-Karyo: A combined service including G-banding karyotyping and the iCS-digital PSC-28 probe assay, specifically designed for human pluripotent stem cells. By combining the broad detection scope of G-banding with the high resolution of iCS-digital PSC, this approach enables a robust and comprehensive genomic characterization, ensuring that frequent small variants undetectable by G-banding alone are not missed. 4) Next-Generation Sequencing (NGS): Enables deeper genomic characterization through the detection of SNVs and indels across a curated panel of 361 genes known to be associated with cancer or recurrently mutated in hPSCs, as well as genome-wide CNV detection using a backbone of probes. All analyses are fully interpreted to support informed decision-making. - Cell Identity: Short Tandem Repeat (STR) profiling is the most widely used method for cell line authentication. STR analysis is recommended at cell acquisition, during the characterization of each cell bank, and on a monthly basis during culture to ensure that the correct material is being used. It is estimated that between 20% and 33% of cell lines used in research are misidentified due to cross-contamination or mislabeling. - Pluripotency and Differentiation Potential: Based on digital PCR, the Pluri-digital assay enables assessment within 5 days of: 1) Pluripotency status using 4 key markers, or 2) Differentiation potential using 12 markers (4 markers per germ layer). - Sterility: The Myco-digital assay, based on digital PCR, detects contamination by 60 mycoplasma species, including the 6 species responsible for approximately 95% of contaminations. The assay offers high sensitivity (>10 CFU/mL). - Customized Assays: We also develop custom digital PCR assays to quantify genes of interest, leveraging the versatility of dPCR for both on-target and off-target applications. Technologies Selected for Stem Cell Characterization: - Digital PCR (dPCR): The most accurate PCR-based method for assessing genetic integrity through the detection of copy number variants (CNVs). It is ideally suited for routine in-process controls and rapid clone screening. - G-banding karyotyping: Provides an exhaustive analysis of large structural and numerical chromosomal variants. - Next-Generation Sequencing (NGS): A hypothesis-free approach that does not require prior knowledge of specific genomic alterations. NGS enables the simultaneous analysis of a large number of genes in a cost-effective manner and is particularly well suited for critical workflow stages such as cell line acquisition, banking, and end-of-workflow validation.

400 Park Offices Drive Room 104, Research Triangle Park Durham, NC, 27703 United StatesStem Genomics is a biotechnology company based in France and the United States, specialized in the design and delivery of innovative testing technologies for stem cells. A spin-out of the Institute for Regenerative Medicine & Biotherapy (IRMB), Stem Genomics was co-founded by Prof. John De Vos and Dr. Said Assou, internationally recognized experts in stem cell genomic integrity. The company emerged from a prestigious scientific environment at the heart of the University Hospital Centre of Montpellier, where the IRMB brings together research teams dedicated to fundamental stem cell research and the development of innovative applications for regenerative medicine, with the goal of accelerating the transfer from research to clinical applications. Founded in 2018, Stem Genomics now works with more than 150 clients worldwide, including academic institutions, biotechnology companies, and core facilities. North American clients are supported through our laboratory located in the Research Triangle in Durham, North Carolina, while European and other international clients are served from our headquarters in Montpellier, France. Stem Genomics is driven by a team of passionate and committed scientists whose mission is to support researchers in generating high-quality, reliable cell lines. We have developed strong in-house expertise in stem cell biology and advanced genetic stability assay technologies, enabling us to perform most analyses on our own platforms. In parallel, our R&D team continuously develops next-generation quality control assays. We pride ourselves on our responsiveness, availability, and close collaboration with our clients throughout the entire testing process. Testing Services Available in Europe and the United States: - Genomic Stability 1) iCS-digital PSC assay: Detects up to 93% of the most frequent abnormalities observed in human pluripotent stem cells within 3 days. The assay relies on a set of 28 specific probes targeting the most frequently affected genomic regions, including the 20q amplification, which represents approximately 23% of recurrent abnormalities in hPSCs and is often too small to be detected by G-banding karyotyping. 2) G-banding karyotype: Detects structural and numerical variants larger than 5–10 Mb. Turnaround time is approximately 20 business days in Europe and 10 business days in the United States. The assay can be performed on live or frozen cells and is applicable to any cell type. 3) Duo iCS-Karyo: A combined service including G-banding karyotyping and the iCS-digital PSC-28 probe assay, specifically designed for human pluripotent stem cells. By combining the broad detection scope of G-banding with the high resolution of iCS-digital PSC, this approach enables a robust and comprehensive genomic characterization, ensuring that frequent small variants undetectable by G-banding alone are not missed. 4) Next-Generation Sequencing (NGS): Enables deeper genomic characterization through the detection of SNVs and indels across a curated panel of 361 genes known to be associated with cancer or recurrently mutated in hPSCs, as well as genome-wide CNV detection using a backbone of probes. All analyses are fully interpreted to support informed decision-making. - Cell Identity: Short Tandem Repeat (STR) profiling is the most widely used method for cell line authentication. STR analysis is recommended at cell acquisition, during the characterization of each cell bank, and on a monthly basis during culture to ensure that the correct material is being used. It is estimated that between 20% and 33% of cell lines used in research are misidentified due to cross-contamination or mislabeling. - Pluripotency and Differentiation Potential: Based on digital PCR, the Pluri-digital assay enables assessment within 5 days of: 1) Pluripotency status using 4 key markers, or 2) Differentiation potential using 12 markers (4 markers per germ layer). - Sterility: The Myco-digital assay, based on digital PCR, detects contamination by 60 mycoplasma species, including the 6 species responsible for approximately 95% of contaminations. The assay offers high sensitivity (>10 CFU/mL). - Customized Assays: We also develop custom digital PCR assays to quantify genes of interest, leveraging the versatility of dPCR for both on-target and off-target applications. Technologies Selected for Stem Cell Characterization: - Digital PCR (dPCR): The most accurate PCR-based method for assessing genetic integrity through the detection of copy number variants (CNVs). It is ideally suited for routine in-process controls and rapid clone screening. - G-banding karyotyping: Provides an exhaustive analysis of large structural and numerical chromosomal variants. - Next-Generation Sequencing (NGS): A hypothesis-free approach that does not require prior knowledge of specific genomic alterations. NGS enables the simultaneous analysis of a large number of genes in a cost-effective manner and is particularly well suited for critical workflow stages such as cell line acquisition, banking, and end-of-workflow validation.

IRMB - Hopital Saint Eloi 80 avenue Augustin Fliche Montpellier Cedex 5, Hérault, 34295 FranceStem Genomics is a biotechnology company based in France and the United States, specialized in the design and delivery of innovative testing technologies for stem cells. A spin-out of the Institute for Regenerative Medicine & Biotherapy (IRMB), Stem Genomics was co-founded by Prof. John De Vos and Dr. Said Assou, internationally recognized experts in stem cell genomic integrity. The company emerged from a prestigious scientific environment at the heart of the University Hospital Centre of Montpellier, where the IRMB brings together research teams dedicated to fundamental stem cell research and the development of innovative applications for regenerative medicine, with the goal of accelerating the transfer from research to clinical applications. Founded in 2018, Stem Genomics now works with more than 150 clients worldwide, including academic institutions, biotechnology companies, and core facilities. North American clients are supported through our laboratory located in the Research Triangle in Durham, North Carolina, while European and other international clients are served from our headquarters in Montpellier, France. Stem Genomics is driven by a team of passionate and committed scientists whose mission is to support researchers in generating high-quality, reliable cell lines. We have developed strong in-house expertise in stem cell biology and advanced genetic stability assay technologies, enabling us to perform most analyses on our own platforms. In parallel, our R&D team continuously develops next-generation quality control assays. We pride ourselves on our responsiveness, availability, and close collaboration with our clients throughout the entire testing process. Testing Services Available in Europe and the United States: - Genomic Stability 1) iCS-digital PSC assay: Detects up to 93% of the most frequent abnormalities observed in human pluripotent stem cells within 3 days. The assay relies on a set of 28 specific probes targeting the most frequently affected genomic regions, including the 20q amplification, which represents approximately 23% of recurrent abnormalities in hPSCs and is often too small to be detected by G-banding karyotyping. 2) G-banding karyotype: Detects structural and numerical variants larger than 5–10 Mb. Turnaround time is approximately 20 business days in Europe and 10 business days in the United States. The assay can be performed on live or frozen cells and is applicable to any cell type. 3) Duo iCS-Karyo: A combined service including G-banding karyotyping and the iCS-digital PSC-28 probe assay, specifically designed for human pluripotent stem cells. By combining the broad detection scope of G-banding with the high resolution of iCS-digital PSC, this approach enables a robust and comprehensive genomic characterization, ensuring that frequent small variants undetectable by G-banding alone are not missed. 4) Next-Generation Sequencing (NGS): Enables deeper genomic characterization through the detection of SNVs and indels across a curated panel of 361 genes known to be associated with cancer or recurrently mutated in hPSCs, as well as genome-wide CNV detection using a backbone of probes. All analyses are fully interpreted to support informed decision-making. - Cell Identity: Short Tandem Repeat (STR) profiling is the most widely used method for cell line authentication. STR analysis is recommended at cell acquisition, during the characterization of each cell bank, and on a monthly basis during culture to ensure that the correct material is being used. It is estimated that between 20% and 33% of cell lines used in research are misidentified due to cross-contamination or mislabeling. - Pluripotency and Differentiation Potential: Based on digital PCR, the Pluri-digital assay enables assessment within 5 days of: 1) Pluripotency status using 4 key markers, or 2) Differentiation potential using 12 markers (4 markers per germ layer). - Sterility: The Myco-digital assay, based on digital PCR, detects contamination by 60 mycoplasma species, including the 6 species responsible for approximately 95% of contaminations. The assay offers high sensitivity (>10 CFU/mL). - Customized Assays: We also develop custom digital PCR assays to quantify genes of interest, leveraging the versatility of dPCR for both on-target and off-target applications. Technologies Selected for Stem Cell Characterization: - Digital PCR (dPCR): The most accurate PCR-based method for assessing genetic integrity through the detection of copy number variants (CNVs). It is ideally suited for routine in-process controls and rapid clone screening. - G-banding karyotyping: Provides an exhaustive analysis of large structural and numerical chromosomal variants. - Next-Generation Sequencing (NGS): A hypothesis-free approach that does not require prior knowledge of specific genomic alterations. NGS enables the simultaneous analysis of a large number of genes in a cost-effective manner and is particularly well suited for critical workflow stages such as cell line acquisition, banking, and end-of-workflow validation.

Cap Sigma 1682 rue de la Valsière Grabels, 34790 FranceStem Genomics is a biotechnology company based in France and the United States, specialized in the design and delivery of innovative testing technologies for stem cells. A spin-out of the Institute for Regenerative Medicine & Biotherapy (IRMB), Stem Genomics was co-founded by Prof. John De Vos and Dr. Said Assou, internationally recognized experts in stem cell genomic integrity. The company emerged from a prestigious scientific environment at the heart of the University Hospital Centre of Montpellier, where the IRMB brings together research teams dedicated to fundamental stem cell research and the development of innovative applications for regenerative medicine, with the goal of accelerating the transfer from research to clinical applications. Founded in 2018, Stem Genomics now works with more than 150 clients worldwide, including academic institutions, biotechnology companies, and core facilities. North American clients are supported through our laboratory located in the Research Triangle in Durham, North Carolina, while European and other international clients are served from our headquarters in Montpellier, France. Stem Genomics is driven by a team of passionate and committed scientists whose mission is to support researchers in generating high-quality, reliable cell lines. We have developed strong in-house expertise in stem cell biology and advanced genetic stability assay technologies, enabling us to perform most analyses on our own platforms. In parallel, our R&D team continuously develops next-generation quality control assays. We pride ourselves on our responsiveness, availability, and close collaboration with our clients throughout the entire testing process. Testing Services Available in Europe and the United States: - Genomic Stability 1) iCS-digital PSC assay: Detects up to 93% of the most frequent abnormalities observed in human pluripotent stem cells within 3 days. The assay relies on a set of 28 specific probes targeting the most frequently affected genomic regions, including the 20q amplification, which represents approximately 23% of recurrent abnormalities in hPSCs and is often too small to be detected by G-banding karyotyping. 2) G-banding karyotype: Detects structural and numerical variants larger than 5–10 Mb. Turnaround time is approximately 20 business days in Europe and 10 business days in the United States. The assay can be performed on live or frozen cells and is applicable to any cell type. 3) Duo iCS-Karyo: A combined service including G-banding karyotyping and the iCS-digital PSC-28 probe assay, specifically designed for human pluripotent stem cells. By combining the broad detection scope of G-banding with the high resolution of iCS-digital PSC, this approach enables a robust and comprehensive genomic characterization, ensuring that frequent small variants undetectable by G-banding alone are not missed. 4) Next-Generation Sequencing (NGS): Enables deeper genomic characterization through the detection of SNVs and indels across a curated panel of 361 genes known to be associated with cancer or recurrently mutated in hPSCs, as well as genome-wide CNV detection using a backbone of probes. All analyses are fully interpreted to support informed decision-making. - Cell Identity: Short Tandem Repeat (STR) profiling is the most widely used method for cell line authentication. STR analysis is recommended at cell acquisition, during the characterization of each cell bank, and on a monthly basis during culture to ensure that the correct material is being used. It is estimated that between 20% and 33% of cell lines used in research are misidentified due to cross-contamination or mislabeling. - Pluripotency and Differentiation Potential: Based on digital PCR, the Pluri-digital assay enables assessment within 5 days of: 1) Pluripotency status using 4 key markers, or 2) Differentiation potential using 12 markers (4 markers per germ layer). - Sterility: The Myco-digital assay, based on digital PCR, detects contamination by 60 mycoplasma species, including the 6 species responsible for approximately 95% of contaminations. The assay offers high sensitivity (>10 CFU/mL). - Customized Assays: We also develop custom digital PCR assays to quantify genes of interest, leveraging the versatility of dPCR for both on-target and off-target applications. Technologies Selected for Stem Cell Characterization: - Digital PCR (dPCR): The most accurate PCR-based method for assessing genetic integrity through the detection of copy number variants (CNVs). It is ideally suited for routine in-process controls and rapid clone screening. - G-banding karyotyping: Provides an exhaustive analysis of large structural and numerical chromosomal variants. - Next-Generation Sequencing (NGS): A hypothesis-free approach that does not require prior knowledge of specific genomic alterations. NGS enables the simultaneous analysis of a large number of genes in a cost-effective manner and is particularly well suited for critical workflow stages such as cell line acquisition, banking, and end-of-workflow validation.